Erenumab shows promise in a subgroup analysis of patients with chronic migraine and medication overuse in a phase 2 trial.
Chronic migraine (CM) — defined as 15 or more headache days per month — can be difficult to treat. It is often accompanied by medication overuse (MO), which is the excessive use of acute medications. MO is distinct from medication-overuse headache (MOH), a secondary headache disorder that can result from MO. Cessation of the implicated acute treatments, initiation of preventive treatment, or both are debated treatment options for CM with MO. Three antibodies to calcitonin gene-related peptide (anti-CGRP), including erenumab, have been FDA-approved for preventive treatment of migraine. Can a preventive therapy, such as erenumab, show benefit in patients with CM and MO?
Investigators conducted a preplanned subgroup analysis of the double-blind…